Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects
- Registration Number
- NCT04982913
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Brief Summary
The Safety, Tolerability, Pharmacokinetic, Food Effect Study and the interaction with Oseltamivir Phosphate Capsules of HEC116094 in Healthy Subjects
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 118
Inclusion Criteria
- Willing to participate in the study, able to understand and sign the informed consent, and able to complete the the study in accordance with the requirements of the study.
- Female subjects who are not pregnant or lactating and male subjects whose female partners are fertile shall voluntarily take effective contraceptive measures from the date of signing the informed consent form to 3 months after the medication.
- When signing the informed consent, 18 years old ≤the age≤45 years old(including the critical value), gender is not limited.
- Male body weight ≥50kg, female body weight ≥45kg, and body mass index (BMI) in the range of 18-28 kg/m2 (including the critical value).
- No clinical significance of vital signs, physical examination, laboratory examination, electrocardiogram, ultrasound abdomen and chest X-ray (posterior and anterior) results.
Exclusion Criteria
- Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis.
- Those who are known to have allergy history or allergy constitution to the test preparation and any of its components or related preparations.
- Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
- Positive results from urine drug screen test.
- Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
- Subjects who plan to receive or have had organ transplants.
- Subjects considered by the investigator to have other factors unsuitable for participation in this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Single dose of HEC116094（Part A, Cohort 1） HEC116094 Healthy subjects receive sinele dose of HEC116094 Single dose of HEC116094（Part A, Cohort 2） HEC116094 Healthy subjects receive sinele dose of HEC116094 or matching placebo Single dose of HEC116094（Part A, Cohort 3） HEC116094 Healthy subjects receive sinele dose of HEC116094 or matching placebo Single dose of HEC116094（Part A, Cohort 4，Fed/Fasting） HEC116094 Following an overnight fast of at least 10 hours, a single dose of HEC116094 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions. Single dose of HEC116094（Part A, Cohort 6） HEC116094 Healthy subjects receive sinele dose of HEC116094 or matching placebo Mulltiple doses HEC116094（ Part B, Cohort 4） HEC116094 Healthy subjects receive multiple doses of HEC116094 or matching placebo Single dose of HEC116094（Part A, Cohort 5） HEC116094 Healthy subjects receive sinele dose of HEC116094 or matching placebo Single dose of HEC116094（Part A, Cohort 7） HEC116094 Healthy subjects receive sinele dose of HEC116094 or matching placebo Mulltiple doses HEC116094（ Part B, Cohort 2） HEC116094 Healthy subjects receive multiple doses of HEC116094 or matching placebo The interaction with Oseltamivir of HEC116094（ Part C） HEC116094 Healthy subjects received HEC116094 in cycle 1, Oseltamivir in cycle 2, and a combination of HEC116094 and Oseltamivir in cycle 3.There are washout periods between the first cycle and the second cycle and between the second cycle and the third cycle Mulltiple doses HEC116094（ Part B, Cohort 1） HEC116094 Healthy subjects receive multiple doses of HEC116094 or matching placebo Mulltiple doses HEC116094（ Part B, Cohort 3） HEC116094 Healthy subjects receive multiple doses of HEC116094 or matching placebo
- Primary Outcome Measures
Name Time Method Safety and Tolerability of HEC116094 by Assessment of the Number of Adverse up to 7 days at Part A and 11 days at Part B and 26 days at Part C To investigate the safety and tolerability of HEC116094 by assessment of AEs
- Secondary Outcome Measures
Name Time Method Cmax up to 72 hours Maximum Plasma Concentration(Cmax)of HEC116094
Tmax up to 72 hours Maximum Peak Time(Tmax) of HEC116094
AUC up to 72 hours Area Under the Curve(AUC) of HEC116094
T1/2 up to 72 hours Maximum Peak Time(Tmax) of HEC116094
Trial Locations
- Locations (1)
The Shanghai xuhui district central hospital
🇨🇳Shanghai, Shanghai, China